Technology comprises conjugate drugs that target bone and release active species for enhanced efficacy and reduced side effects. Initial product for rapid integration of bone implants. New products for myelofibrosis, brittle bone disease and cancer in pipeline. Virtual company model with primary research at SFU and UBC. Initial target market, bone generation for dental and orthopaedic implants, representing $ multibillion markets.